Ajanta Pharma is pushing into new regions and focusing on long‑term medicines, a move that could help the company grow steadily.
Key Takeaways
- The company is targeting larger markets in Asia and Africa.
- It is expanding its product range to include chronic‑disease drugs.
- A partnership with Biocon will bring semaglutide to 23 countries.
- These steps aim to create new demand and capture market share.
Growth Strategy
Ajanta Pharma plans to grow in two ways:
- Add new geographies: Moving into bigger markets will broaden its reach.
- Deepen existing offerings: Introducing more products, especially for chronic conditions, should provide stable revenue.
The Biocon tie‑up gives Ajanta access to a modern therapy (semaglutide) that the original maker does not widely sell, letting Ajanta become a market pioneer in those countries.
Valuation and Recommendation
Motilal Oswal values Ajanta Pharma at 30 times its projected earnings for the next 12 months, which leads to a target price of about INR 3,145 per share. The firm repeats its “Buy” call on the stock.
Disclaimer
Remember, this is an opinion, not a guarantee. Do your own research and consider speaking with a qualified financial advisor before making any investment decisions.